Myriad Genetics, Inc.’s MYGN Oncology growth strategy, which focuses on expanding companion diagnostics and market growth through new clinical guidelines, is poised to drive growth in the ...

In the preceding three months, 10 analysts have released ratings for Myriad Genetics (NASDAQ:MYGN), presenting a wide array of perspectives from bullish to bearish. Summarizing their recent ...